Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01371565 · ClinicalTrials.gov registry record · Phase 3
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
A Phase 3 study, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 4
- Enrollment target
NCT01371565: Completed Phase 3 study, sponsored by Corcept Therapeutics.
NCT01371565 is a Phase 3 study that has completed, run by Corcept Therapeutics. The registered enrollment target is 4 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01371565, a Phase 3 study, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome when given on a compassionate use basis. The study will only enroll subjects whose physicians have determined that medical treatment is needed to control the symptoms or signs of hypercortisolemia.
Primary Outcome
Safety was assessed at all visits and adverse events were recorded.
Interventions
- DRUG Mifepristone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
What the finished NCT01371565 record still lists
NCT01371565 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Mifepristone is the first listed.
NCT01371565 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01371565 about?
NCT01371565 is a clinical study titled "Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome". This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome when given on a compassionate use basis...
What is the current status of trial NCT01371565?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2010-11. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01371565?
The interventions under investigation include: Mifepristone (DRUG).
Who is sponsoring clinical trial NCT01371565?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01371565's enrollment target sits among peer trials
4 1998th of 2000 higher than 2 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia